Ad-p27mt转染重组腺病毒治疗裸鼠内人胃癌的分子机制

目的:研究Ad-p27mt转染重组腺病毒对人胃癌细胞凋亡的作用及机制.方法:Ad-p27mt转染重组腺病毒导入胃癌细胞株SGC-7901内;流式细胞仪检测凋亡染色体亚二倍体峰值,了解Ad-p27mt对人胃癌组织凋亡的作用;TUNEL法检测DNA片断,在Ad-p27mt组和Ad-LacZ组中分析细胞的凋亡.结果:Ad-p27mt成功转入人胃癌细胞SGC-7901内,转化率达100%.流式细胞仪检测发现在感染后18h出现G1-S相前出现凋亡染色体亚二倍体峰值,并且DNA电泳出现凋亡特征性的条带;TUNEL法检测Ad-p27治疗组与对照组的凋亡率分别是92.3%±3.76%和2.01%±0.15%,两组的差异有显著性(P<0.01).结论:重组腺病毒转染的人p27突变基因能诱导裸鼠体内人胃癌细胞SGC-7901的凋亡.     

Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells

The CXC chemokines, IP-10/CXCL10 and IL-8/CXCL8, play a role in obstructive lung disease by attracting Th1/Tc1 lymphocytes and neutrophils, respectively. Inhaled corticosteroids (ICS) and long acting beta 2-agonists (LABA) are widely used. However, their effect(s) on the release of IP-10 and IL-8 by airway epithelial cells are poorly understood. This study examined the effects of fluticasone, salmeterol, and agents which raise intracellular cAMP (cilomilast and db-cAMP) on the expression of IP-10 and IL-8 protein and mRNA. Studies were performed in cultured human airway epithelial cells during cytokine-stimulated IP-10 and IL-8 release. Cytokine treatment (TNF-alpha, IL-1beta and IFN-gamma) increased IP-10 and IL-8 protein and mRNA levels. Fluticasone (0.1 nM to 1 microM) increased IP-10 but reduced IL-8 protein release without changing IP-10 mRNA levels assessed by real time RT-PCR. The combination of salmeterol (1 micro M) and cilomilast (1-10 mu M) reduced IP-10 but had no effect on IL-8 protein. Salmeterol alone (1 micro M) and db-cAMP alone (1 mM) antagonised the effects of fluticasone on IP-10 but not IL-8 protein. In human airway epithelial cells, inhibition by salmeterol of fluticasone-enhanced IP-10 release may be an important therapeutic effect of the LABA/ICS combination not present when the two drugs are used separately.     

基质金属蛋白酶-9在脑缺血过程中的双重作用

基质金属蛋白酶-9(MMP-9)是MMP家庭中的一员,可特异性降解细胞外基质。脑缺血早期(1～3d),MMP-9可通过降解基底膜及内皮细胞紧密连接破坏血脑屏障,导致继发性脑水肿和脑出血。脑缺血后期(7～14d),MMP-9则能促进神经血管再生,有利于损伤脑组织的恢复。     

Correlation study of in vitro tests with clinical response to ALG therapy in patients with severe aplastic anemia

Fourteen patients with severe aplastic anemia were treated with antilymphocyte globulin (ALG). Eight were studied with co-culture of patient's lymphocytes with normal bone marrow cells. Suppression of CFU-C was prevented by pretreatment of T lymphocytes with anti-T lymphocyte McAb in four patients and concordance with clinical outcome was observed only in two patients. Conclusive in vivo therapy result for this correspondence are lacking. Seven patients received fetal liver cell suspension infusion 24-36 hours after completing ALG therapy and remission were "more complete" in three cases with good response. Response of treatment in the fourteen patients was as follows: eight had complete or partial responses and the remaining did not respond or died (42.8%).     

三级医院团队与社会药房执业药师合作 管理糖尿病模式的探索

目的：社会药房的执业药师经过由三级医院构建的糖尿病管理团队的培训,对在本店配药的糖尿病患者进行管理,探讨社会药房执业药师的糖尿病管理模式。方法：经三级医院团队培训后的社会药房执业药师,对本店的糖尿病患者进行健康宣教及药学服务,患者随机分为对照组和试验组,试验组接受执业药师的药学服务,对照组未接受执业药师服务。结果：接受执业药师管理的患者前后体重指数（BMI）、收缩压（SBP）、空腹血糖（FPG）、餐后2小时血糖（2 h PPG）、糖化血红蛋白（HbA1c）、用药依从性都有明显改变,且腰臀比（WHR）、SBP、2hPPG、HbA1c、用药依从性等指标改善显著优于对照组,仅WHR、舒张压（DBP）无显著改善;未接受管理的患者,随访前后指标无显著差异。结论：经培训的社会药房执业药师在糖尿病管理工作中发挥着重要的作用,可明显改善糖尿病患者BMI、WHR、血压、血糖、用药依从性等指标;此模式为社会药房执业药师工作模式的探索提供了一种方案。     

住院患儿肺炎合并胸腔积液病原学特点分析

目的：探讨住院患儿肺炎合并胸腔积液的病原学特点,为肺炎合并胸腔积液患儿合理诊疗提供病原学参考。方法：收集2010年1月至2018年12月苏州大学附属儿童医院收治的361例肺炎合并胸腔积液住院患儿的病历资料及痰标本。采用直接免疫荧光法检测7种常见呼吸道病毒,荧光定量聚合酶链式反应（PCR）法检测肺炎支原体（MP）、肺炎衣原体（CP）及博卡病毒（HBoV）、结核杆菌,逆转录-聚合酶链式反应（RT-PCR）法检测鼻病毒（HRV）及偏肺病毒（hMPV）,并进行细菌培养。入院24 h内及治疗7~10 d采集患儿静脉血,采用ELISA法检测血清特异性MP抗体IgG、IgM。结果：361例肺炎合并胸腔积液患儿总病原学检出率为82.83%,其中MP检出率67.59%,病毒检出率15.51%,细菌检出率19.39%,混合感染检出率20.50%,结核杆菌检出率2.22%。病毒检出以hBoV、HRV为主,细菌检出以肺炎链球菌（SP）、流感嗜血杆菌（HI）为主,混合感染以细菌+MP、病毒+MP混合感染为主。肺炎合并胸腔积液患儿病毒在1~3岁组检出率最高,>6岁组患儿病毒检出率最低（P<0.05）,MP检出率随着年龄的增加逐渐升高（P<0.05）。1~3岁组、>3~6岁组患儿细菌检出率均明显高于>6岁组（P<0.05）,1~3岁组患儿混合感染率最高（P<0.05）。MP夏季检出率最高,春季检出率最低（P<0.05）,病毒夏季检出率相对较低,而细菌秋冬季节检出率相对较高。结论：MP为肺炎合并胸腔积液最重要的病原体,尤其在夏秋季节,其次为SP,随着年龄增大MP检出率越高,混合感染及结核感染也不容忽视。     

Fecal microbiota changes with fermented kimchi intake regulated either formation or advancement of colon adenoma

Gut bacteria might contribute in early stage of colorectal cancer through the development and advancement of colon adenoma, by which exploring either beneficial bacteria, which are decreased in formation or advancement of colon adenoma and harmful bacteria, which are increased in advancement of colon adenoma may result in implementation of dietary interventions or probiotic therapies to functional means for prevention. Korean fermented kimchi is one of representative probiotic food providing beneficiary microbiota and exerting significant inhibitory outcomes in both APC/^Min+ polyposis model and colitis-associated cancer. Based on these backgrounds, we performed clinical trial to document the changes of fecal microbiota in 32 volunteers with normal colon, simple adenoma, and advanced colon adenoma with 10 weeks of fermented kimchi intake. Each amplicon is sequenced on MiSeq of Illumina and the sequence reads were clustered into Operational Taxonomic Units using VSEARCH and the Chao Indices, an estimator of richness of taxa per individual, were estimated to measure the diversity of each sample. Though significant difference in α or β diversity was not seen between three groups, kimchi intake significantly led to significant diversity of fecal microbiome. After genus analysis, Acinobacteria, Cyanobacteria, Clostridium sensu, Turicibacter, Gastronaeophillales, H. pittma were proven to be increased in patients with advanced colon adenoma, whereas Enterococcua Roseburia, Coryobacteriaceau, Bifidobacterium spp., and Akkermansia were proven to be significantly decreased in feces from patients with advanced colon adenoma after kimchi intake. Conclusively, fermented kimchi plentiful of beneficiary microbiota can afford significant inhibition of either formation or advancement of colon adenoma.